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In this issue of haematologica, Reimer et al.
1 present an
improved strategy based on genome engineering, viral
vector transduction, and the use of CD34+ human
hematopoietic stem and progenitor cells (HPSCs) to recreate
a human leukemic chromosomal rearrangement,
t(11;19)/MLL-ENL, in its natural genomic environment. This
model provides new clues as to the complex molecular
mechanisms of mixed-lineage-rearranged (MLLr) leukemia
and opens up new avenues for the genomic reconstruction to
study leukemia initiation and evolution.
A common and disease/lineage-specific molecular signa-
ture of leukemia involves the generation of recurrent recip-
rocal chromosomal translocations, which are considered to
be the oncogenic initiating drivers.2 Chromosomal genomic
rearrangements are complex and implicate illegitimate
recombination or juxtaposition of normally separated genes
during DNA replication, and results in oncogene activation
or, more commonly in leukemia, the generation of novel
fusion genes.3 Our current understanding on how the nature
of the target cell and the spatial organization of chromo-
somes in the nucleus contribute to chromosomal rearrange-
ments (i.e. translocations) is very limited. Questions about
the nature of the target cell in which the translocation arises
and initiates leukemia can not really be studied with primary
patient samples because all molecular insults are in place at
the time of disease presentation.4-6 As an alternative, patient-
derived cell lines have been widely exploited to study the
contribution of translocations to leukemogenesis; however,
associated problems can arise when using this material.
Human cancer cell lines are generated from primary cells
once the full transformation events have taken place, and
this can present challenges for distinguishing between driver
and passenger events. Moreover, serial passage of cell lines
can cause genotypic variation, and even heterogeneity in cul-
tures, resulting in a loss of information on the leukemia ini-
tiation and the different steps of progression.7 These caveats
aside, cell lines are powerful tools for ascertaining and char-
acterizing the cancer gene, and have over recent decades
increased our general understanding of the molecular patho-
physiology of chromosomal rearranged leukemia.8 Beyond in
vitro studies, genetically modified animal and cellular models
constitute invaluable tools for cancer investigation, but they
also have limitations, due in part to the manner in which
they are generated. Most of the extensively used leukemia
models are generated using viral vector-based approaches
(primarily recombinant retroviruses and lentiviruses), ran-
domly integrated plasmid DNA or, in a more refined man-
ner, by generating “knock-in” fusion genes.5,6,9,10 Some of the
major concerns regarding these methodologies are: i) the
high potential mutagenic rate associated with uncontrolled
cassette integration that could lead to a growth advantage
and variegated cell lines (for plasmid DNA and integrative
recombinant virus approaches); ii) an exogenous strong
transgene expression controlled by promoters that function
in a broad range of cells; or iii) the expression of just one of
the fusion genes generated by a chromosomal translocation
and the retention of the two wild-type alleles (for the
“knock-in” strategy) which is not seen in patients.11
These concerns guide the search for more faithful models
capable of recapitulating the initial genetic events associated
with the leukemogenic process with the least alteration in
the genomic architecture. Until recently, the most effective
way to replicate these events was based on the generation of
chromosomal translocations using translocator technology.
This approach involves the use of the Cre/loxP site-specific
system via prior engineering in the mouse genome.12 While
some leukemia animal and cellular models have been suc-
cessfully developed using this strategy, its use in human cells
is extremely inefficient. More recently, the explosion of new
genome editing technologies, particularly the CRISPR/Cas9
system, has permitted the efficient recreation of de novo can-
cer-associated translocations in vitro in mouse and human
cells,13 and in vivo in mouse models.14 This is important
because it has been demonstrated that, although conditional
models or viral vector expression systems can efficiently
generate chromosomal translocations, the engineered cells
do not always initiate a leukemic-like phenotype in mouse
xenograft models. 
In the present article, Reimer et al.1 combine the unde-
manding aspects of lentiviral generation and delivery with
the advantages of chromosomal translocation generation by
the CRISPR system. The authors engineered an advanced
lentiviral CRISPR/Cas9 vector for efficient transduction of
human CD34+ HPSCs. This new lentiviral vector permits the
induction of double strand breaks (DSBs) in the MLL and
ENL intronic regions with very high efficiency (78-83%),
favoring the generation of the t(11;19) rearrangement. As a
consequence of the translocation, two derivative chromo-
somes are generated, der(11) and der(19), leading to the
expression of both fusion transcripts and the concomitant
loss of one copy of the wild-type MLL and ENL genes. The
authors describe a transient outgrowth advantage in long-
term cultures of the primary human CD34+ HSPCs t(11;19)+,
but more significantly, they demonstrated that when these
cells were injected into primary immunodeficient recipients,
the in vivo environment favored oncogenic transformation,
initiating a monocytic leukemia-like disease. It is important
to emphasize that whereas this transformative process does
not fully recapitulate the human leukemic phenotype in
primary recipients, secondary recipients developed acute
lymphoblastic leukemia, albeit with incomplete pene-
trance. Based on these findings, the authors conclude that
“environmental cues not only contribute to the disease
phenotype, but also to t(11;19)/MLL-ENL-mediated onco-
genic transformation”.1 This result resembles the effect of
chemotherapy in patients, but it will need to be con-
firmed in future studies.
While the results described in this study represent a great
improvement in the field, some questions remain and
some issues have still not been fully clarified. For example,
although the authors demonstrated an extremely high DSB
induction efficiency, the translocation rate remained very
low (0.2% or 1.6*10-3), even when compared with other
publications.13,15,16 This could be due to the genome archi-
tecture of the leukemia-initiating cell, the proximity
between involved loci or the presence of repetitive ele-
ments.17 In addition, although it is a more advantageous
model due to the conservation of all endogenous regulato-
ry elements (promoters, enhancers, miRNA binding sites
and rearranged genome architecture) and the possibility to
study the initial steps of the leukemic process, the
approach is grounded on the use of random integrative
lentiviruses, which could lead to mutagenic effects and
growth advantages associated with their integration pat-
tern. Moreover, the continuous expression of the
CRISPR/Cas9 components may increase the likelihood of
undesirable off-target effects over time. Regarding this lat-
ter issue, two alternative approaches have recently been
described that could further improve the use of the CRISPR
system in the generation of leukemic models. The first one
relies on the use of a “hit-and-run” protein-based Cas9 sys-
tem that circumvents the lentiviral integration concerns
and lessens the chances of off-target effects while permit-
ting the generation of human chromosomal translocations
in a wide variety of primary stem cells with higher efficien-
cies.16 The second approach takes advantage of the classical
“knock-in” model, but with application to human cells
with conditional allele expression and resistance selection
cassettes in combination with the CRISPR/Cas9 system.15
Because of their inducible nature, both approaches could
widen our knowledge of the first steps leading to the estab-
lishment of cancer and to its progression.
The CRISPR/Cas9 system has revolutionized function-
al biology, biotechnology, and genomic medicine. The
present article by Reimer et al.1 illustrates how the use of
more accurate models generated by genome engineering
techniques in human CD34+ HPSCs can transform the
field of  basic leukemia biology. A deeper knowledge of
the CRISPR approach and the development of new appli-
cations should open new horizons for the study of the
molecular and cellular processes of cancer, and will make
it easier to reproduce the complex cancer genome and
epigenome, allowing a more rigorous molecular analysis
of the molecular mechanisms involved in tumor progres-
sion and the identification of oncogenes and tumor sup-
pressor genes. Specifically, further developments to iso-
late the minor fraction of bona fide genome-edited CD34+
clones (via antibiotic selection, reporter expression, etc.)
would open up fascinating new avenues in the study of
leukemia and cancer modeling. 
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